Literature DB >> 33628115

Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation.

Ao Ren1,2,3, Zhongqiu Li1,2,3, Pengrui Cheng1,2,3, Xuzhi Zhang1,2,3, Ronghai Deng1,2,3, Yi Ma1,2,3.   

Abstract

BACKGROUND: It was reported that systemic immune inflammation index (SII) was related to poor prognosis in a variety of cancers. We aimed to investigate the ability of the prognostic predictors of SII in patients with intrahepatic cholangiocarcinoma (iCCA) undergoing liver transplantation (LT).
METHODS: The 28 iCCA patients who underwent LT at our hospital between 2013 and 2018 were reviewed. Kaplan-Meier survival curves and Cox regression analyses were used to evaluate the prognostic significance of SII. Patients were divided into the high and low SII groups according to the cut-off value.
RESULTS: The 1-, 3-, and 5-year OS rates were significantly lower in the high SII group (85.7%, 28.6%, and 21.4%, respectively) than in the low SII group (92.9%, 71.4%, and 57.2%, respectively; P = 0.009). The 1-, 3-, and 5-year RFS rates were, respectively, 57.1%, 32.7%, and 21.8% in the high SII group and 85.7%, 61.1%, and 61.1% in the low SII group (P = 0.021). SII ≥ 447.48 × 109/L (HR 0.273, 95% CI 0.082-0.908; P = 0.034) was an independent prognostic factor for OS.
CONCLUSIONS: Our results showed that SII can be used to predict the survival of patients with iCCA who undergo LT.
Copyright © 2021 Ao Ren et al.

Entities:  

Mesh:

Year:  2021        PMID: 33628115      PMCID: PMC7899762          DOI: 10.1155/2021/6656996

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  38 in total

Review 1.  The platelet contribution to cancer progression.

Authors:  N M Bambace; C E Holmes
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

2.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

Authors:  John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

3.  Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.

Authors:  G Sapisochin; M Facciuto; L Rubbia-Brandt; J Marti; N Mehta; F Y Yao; E Vibert; D Cherqui; D R Grant; R Hernandez-Alejandro; C H Dale; A Cucchetti; A Pinna; S Hwang; S G Lee; V G Agopian; R W Busuttil; S Rizvi; J K Heimbach; M Montenovo; J Reyes; M Cesaretti; O Soubrane; T Reichman; J Seal; P T W Kim; G Klintmalm; C Sposito; V Mazzaferro; P Dutkowski; P A Clavien; C Toso; P Majno; N Kneteman; C Saunders; J Bruix
Journal:  Hepatology       Date:  2016-08-24       Impact factor: 17.425

4.  Comparison of Preoperative Inflammation-based Prognostic Scores in Patients With Colorectal Cancer.

Authors:  Yoshiyuki Suzuki; Koji Okabayashi; Hirotoshi Hasegawa; Masashi Tsuruta; Kohei Shigeta; Takayuki Kondo; Yuko Kitagawa
Journal:  Ann Surg       Date:  2018-03       Impact factor: 12.969

5.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

6.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

7.  The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma.

Authors:  Stefan Buettner; Gaya Spolverato; Charles W Kimbrough; Sorin Alexandrescu; Hugo P Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Matthew Weiss; Todd W Bauer; Feng Shen; George A Poultsides; J Wallis Marsh; Jan N M IJzermans; Bas Groot Koerkamp; Timothy M Pawlik
Journal:  Surgery       Date:  2018-06-11       Impact factor: 3.982

8.  Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.

Authors:  Pranav Murthy; Mazen S Zenati; Amr I Al Abbas; Caroline J Rieser; Nathan Bahary; Michael T Lotze; Herbert J Zeh; Amer H Zureikat; Brian A Boone
Journal:  Ann Surg Oncol       Date:  2019-12-02       Impact factor: 5.344

Review 9.  Neutrophils in cancer: neutral no more.

Authors:  Seth B Coffelt; Max D Wellenstein; Karin E de Visser
Journal:  Nat Rev Cancer       Date:  2016-06-10       Impact factor: 60.716

10.  Verification of inflammation-based prognostic marker as a prognostic indicator in hepatocellular carcinoma.

Authors:  Masateru Yamamoto; Tsuyoshi Kobayashi; Shintaro Kuroda; Michinori Hamaoka; Sho Okimoto; Naruhiko Honmyo; Megumi Yamaguchi; Hideki Ohdan
Journal:  Ann Gastroenterol Surg       Date:  2019-09-20
View more
  3 in total

1.  Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients.

Authors:  Buwen Zhang; Weiyun Yao
Journal:  World J Surg Oncol       Date:  2022-09-29       Impact factor: 3.253

2.  Association between SII and hepatic steatosis and liver fibrosis: A population-based study.

Authors:  Ruijie Xie; Mengde Xiao; Lihong Li; Nengqian Ma; Mingjiang Liu; Xiongjie Huang; Qianlong Liu; Ya Zhang
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

3.  Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis.

Authors:  Mingyu Jin; Shaoying Yuan; Yiming Yuan; Luqi Yi
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.